Novartis Net Debt from 2010 to 2024

NVS Stock

USD 104.87 1.06 1.02%

Novartis Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt will likely drop to about 11 B in 2024. Net Debt is the total debt of Novartis AG ADR minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2000-06-30

Previous Quarter

21.1 B

Current Value

18.6 B

Quarterly Volatility

11 B

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many indicators such as Price To Sales Ratio of 3.86, Dividend Yield of 0.0241 or PTB Ratio of 3.23. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.

Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Net Debt Growth Pattern

Below is the plot of the Net Debt of Novartis AG ADR over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Novartis' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Novartis Net Debt Regression Statistics

	Arithmetic Mean	15,511,197,536
	Geometric Mean	13,260,738,157
	Coefficient Of Variation	40.72
	Mean Deviation	4,676,029,624
	Median	16,795,000,000
	Standard Deviation	6,316,619,798
	Sample Variance	39899685.7T
	Range	27.2B
	R-Value	0.44
	Mean Square Error	34543243T
	R-Squared	0.20
	Significance	0.1
	Slope	625,452,523
	Total Sum of Squares	558595599.4T

Novartis Net Debt History

	2024	11 B
	2023	13 B
	2022	20.4 B
	2021	18.7 B
	2020	28.4 B
	2019	18.2 B
	2018	18.8 B

Other Fundumenentals of Novartis AG ADR

Net Debt To E B I T D A

Novartis Net Debt component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Intangible Assets	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.92	0.52	0.71	0.92	0.92	0.76	-0.01	0.88	0.41	-0.07	0.55	-0.07	0.93	0.76	0.98	-0.06	0.83	0.1	0.37	0.26	-0.36	0.19	0.29	0.26	0.04
Total Stockholder Equity	0.92		0.65	0.43	0.99	0.83	0.76	-0.08	0.62	0.26	0.12	0.28	0.12	0.77	0.47	0.92	-0.28	0.88	0.42	0.25	0.38	-0.27	-0.14	0.17	0.45	0.18
Current Deferred Revenue	0.52	0.65		0.12	0.69	0.35	0.22	-0.26	0.26	0.04	0.1	-0.07	0.1	0.33	0.28	0.47	-0.27	0.44	0.46	0.21	0.5	-0.72	-0.16	0.03	0.31	0.1
Net Debt	0.71	0.43	0.12		0.47	0.61	0.55	0.14	0.88	0.23	-0.25	0.62	-0.25	0.85	0.91	0.68	0.15	0.35	-0.43	0.36	0.15	-0.29	0.58	0.24	-0.05	-0.18
Retained Earnings	0.92	0.99	0.69	0.47		0.82	0.74	-0.06	0.65	0.28	0.08	0.27	0.08	0.79	0.53	0.92	-0.23	0.85	0.4	0.3	0.37	-0.36	-0.09	0.19	0.41	0.2
Accounts Payable	0.92	0.83	0.35	0.61	0.82		0.68	-0.01	0.84	0.43	-0.12	0.49	-0.12	0.87	0.66	0.94	-0.06	0.87	-0.01	0.18	0.09	-0.28	0.14	0.15	0.07	0.02
Net Receivables	0.76	0.76	0.22	0.55	0.74	0.68		-0.16	0.6	0.11	0.0	0.35	0.0	0.75	0.5	0.82	-0.25	0.78	0.21	0.27	0.23	0.06	0.05	0.15	0.25	0.01
Short Term Investments	-0.01	-0.08	-0.26	0.14	-0.06	-0.01	-0.16		0.08	0.67	-0.12	-0.06	-0.12	0.08	0.17	-0.03	0.19	-0.35	-0.16	0.05	-0.53	-0.01	0.2	0.24	0.01	0.76
Total Liab	0.88	0.62	0.26	0.88	0.65	0.84	0.6	0.08		0.49	-0.27	0.75	-0.27	0.92	0.93	0.85	0.2	0.59	-0.29	0.43	0.08	-0.39	0.53	0.37	-0.02	-0.12
Total Current Assets	0.41	0.26	0.04	0.23	0.28	0.43	0.11	0.67	0.49		-0.38	0.36	-0.38	0.36	0.48	0.36	0.36	0.11	-0.15	0.35	-0.57	-0.34	0.42	0.51	-0.12	0.58
Capital Stock	-0.07	0.12	0.1	-0.25	0.08	-0.12	0.0	-0.12	-0.27	-0.38		-0.25	1.0	-0.19	-0.39	-0.05	-0.78	0.03	0.72	-0.36	0.67	0.48	-0.77	-0.37	0.84	-0.11
Short Term Debt	0.55	0.28	-0.07	0.62	0.27	0.49	0.35	-0.06	0.75	0.36	-0.25		-0.25	0.62	0.62	0.49	0.36	0.29	-0.35	0.59	-0.04	-0.06	0.52	0.51	0.0	-0.36
Common Stock	-0.07	0.12	0.1	-0.25	0.08	-0.12	0.0	-0.12	-0.27	-0.38	1.0	-0.25		-0.19	-0.39	-0.05	-0.78	0.03	0.72	-0.36	0.67	0.48	-0.77	-0.37	0.84	-0.11
Intangible Assets	0.93	0.77	0.33	0.85	0.79	0.87	0.75	0.08	0.92	0.36	-0.19	0.62	-0.19		0.83	0.93	0.05	0.69	-0.12	0.42	0.13	-0.31	0.33	0.3	0.11	0.02
Long Term Debt	0.76	0.47	0.28	0.91	0.53	0.66	0.5	0.17	0.93	0.48	-0.39	0.62	-0.39	0.83		0.71	0.3	0.38	-0.36	0.51	0.04	-0.53	0.71	0.41	-0.13	-0.04
Good Will	0.98	0.92	0.47	0.68	0.92	0.94	0.82	-0.03	0.85	0.36	-0.05	0.49	-0.05	0.93	0.71		-0.14	0.87	0.12	0.3	0.22	-0.29	0.11	0.18	0.24	0.04
Treasury Stock	-0.06	-0.28	-0.27	0.15	-0.23	-0.06	-0.25	0.19	0.2	0.36	-0.78	0.36	-0.78	0.05	0.3	-0.14		-0.21	-0.63	0.41	-0.53	-0.26	0.76	0.5	-0.6	0.07
Property Plant Equipment	0.83	0.88	0.44	0.35	0.85	0.87	0.78	-0.35	0.59	0.11	0.03	0.29	0.03	0.69	0.38	0.87	-0.21		0.27	0.07	0.31	-0.12	-0.11	-0.01	0.22	-0.09
Net Tangible Assets	0.1	0.42	0.46	-0.43	0.4	-0.01	0.21	-0.16	-0.29	-0.15	0.72	-0.35	0.72	-0.12	-0.36	0.12	-0.63	0.27		0.0	0.52	0.2	-0.74	-0.05	0.8	0.28
Deferred Long Term Liab	0.37	0.25	0.21	0.36	0.3	0.18	0.27	0.05	0.43	0.35	-0.36	0.59	-0.36	0.42	0.51	0.3	0.41	0.07	0.0		-0.06	-0.27	0.5	0.81	0.04	0.1
Long Term Investments	0.26	0.38	0.5	0.15	0.37	0.09	0.23	-0.53	0.08	-0.57	0.67	-0.04	0.67	0.13	0.04	0.22	-0.53	0.31	0.52	-0.06		0.02	-0.38	-0.21	0.66	-0.44
Short Long Term Debt	-0.36	-0.27	-0.72	-0.29	-0.36	-0.28	0.06	-0.01	-0.39	-0.34	0.48	-0.06	0.48	-0.31	-0.53	-0.29	-0.26	-0.12	0.2	-0.27	0.02		-0.4	-0.19	0.33	-0.12
Long Term Debt Total	0.19	-0.14	-0.16	0.58	-0.09	0.14	0.05	0.2	0.53	0.42	-0.77	0.52	-0.77	0.33	0.71	0.11	0.76	-0.11	-0.74	0.5	-0.38	-0.4		0.5	-0.57	-0.08
Cash And Equivalents	0.29	0.17	0.03	0.24	0.19	0.15	0.15	0.24	0.37	0.51	-0.37	0.51	-0.37	0.3	0.41	0.18	0.5	-0.01	-0.05	0.81	-0.21	-0.19	0.5		-0.03	0.3
Net Invested Capital	0.26	0.45	0.31	-0.05	0.41	0.07	0.25	0.01	-0.02	-0.12	0.84	0.0	0.84	0.11	-0.13	0.24	-0.6	0.22	0.8	0.04	0.66	0.33	-0.57	-0.03		0.1
Net Working Capital	0.04	0.18	0.1	-0.18	0.2	0.02	0.01	0.76	-0.12	0.58	-0.11	-0.36	-0.11	0.02	-0.04	0.04	0.07	-0.09	0.28	0.1	-0.44	-0.12	-0.08	0.3	0.1

Click cells to compare fundamentals

About Novartis Financial Statements

Novartis shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	13 B	11 B
Net Debt To EBITDA	0.71	0.49

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novartis Net Debt from 2010 to 2024

Latest Novartis' Net Debt Growth Pattern

Novartis Net Debt Regression Statistics

Novartis Net Debt History

Other Fundumenentals of Novartis AG ADR

Novartis Net Debt component correlations

About Novartis Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Novartis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY